We are live on ! Find out more
IMRX icon

Immuneering
IMRX

37 hedge funds and large institutions have $200M invested in Immuneering in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 20 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 4

1.53% more ownership

Funds ownership: 46.67% → 48.19% (+1.5%)

3% less funds holding

Funds holding: 38 → 37 (-1)

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

37% less capital invested

Capital invested by funds: $316M → $200M (-$116M)

Holders
37
Holders Change
-1
Holders Change %
-2.63%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
20
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$7.64M
2
BlackRock
BlackRock
New York
+$4.67M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$1.81M
4
CAM
Cormorant Asset Management
Massachusetts
+$1.22M
5
State Street
State Street
Massachusetts
+$456K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.1M
2
Millennium Management
Millennium Management
New York
-$1.46M
3
CCM
CAAS Capital Management
New York
-$1.06M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$723K
5
GCM
Ghisallo Capital Management
Massachusetts
-$398K
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$50.7M +$1.81M +74,480 +2%
CAM
2
Cormorant Asset Management
Massachusetts
$37.2M +$1.22M +50,000 +2%
Citadel Advisors
3
Citadel Advisors
Florida
$32M +$64.3K +2,643 +0.1%
BlackRock
4
BlackRock
New York
$27.8M +$4.67M +191,796 +13%
RSCM
5
Rock Springs Capital Management
Maryland
$17.6M – – –
PA
6
Perceptive Advisors
New York
$11M – – –
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$5.08M +$7.64M +314,000 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$5.08M -$723K -29,688 -9%
SCM
9
Suvretta Capital Management
New York
$3.23M – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$2.16M +$280K +11,496 +9%
State Street
11
State Street
Massachusetts
$1.94M +$456K +18,739 +19%
Fidelity Investments
12
Fidelity Investments
Massachusetts
$1.32M -$4.1M -168,296 -67%
Northern Trust
13
Northern Trust
Illinois
$1.23M +$79.8K +3,279 +5%
TD Asset Management
14
TD Asset Management
Ontario, Canada
$555K – – –
Millennium Management
15
Millennium Management
New York
$481K -$1.46M -60,032 -67%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$386K +$79.7K +3,276 +16%
Charles Schwab
17
Charles Schwab
California
$346K +$28.3K +1,161 +6%
KPW
18
Kore Private Wealth
New York
$293K +$97.3K +4,000 +28%
N
19
Nuveen
North Carolina
$247K – – –
Goldman Sachs
20
Goldman Sachs
New York
$213K +$320K +13,162 New
Morgan Stanley
21
Morgan Stanley
New York
$172K +$95.6K +3,929 +59%
Wells Fargo
22
Wells Fargo
California
$165K +$247K +10,146 +23,059%
Allspring Global Investments
23
Allspring Global Investments
North Carolina
$149K +$225K +9,228 New
Bank of America
24
Bank of America
North Carolina
$125K +$175K +7,190 +1,327%
JP Morgan Chase
25
JP Morgan Chase
New York
$88K +$55.7K +2,287 +72%
1
2

IMRX Hedge Fund Activity: Q4 2021 in Review

37 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q4 2021, worth a combined $200M — down 37% from $316M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of IMRX and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 20 added.

The largest buyer was Adage Capital Partners, opening a new position worth an estimated $7.64M. The largest seller was Fidelity Investments, cutting an estimated $4.1M.

  • 37 institutional investors held Immuneering (IMRX) as of Q4 2021, down from 38 in Q3 2021.
  • Funds reported $200M of Immuneering stock for Q4 2021, down 37% quarter-over-quarter.
  • 4 funds opened new Immuneering positions in Q4 2021 and 5 closed out, a net change of -1 holder.
  • The largest Immuneering buyer in Q4 2021 was Adage Capital Partners, an estimated $7.64M added.
  • The largest Immuneering seller in Q4 2021 was Fidelity Investments, an estimated $4.1M sold.

Based on aggregated 13F filings for Q4 2021.